Top > Search of International Patents > Cells for producing influenza virus and method for producing influenza virus

Cells for producing influenza virus and method for producing influenza virus

Foreign code F200010177
File No. E096P08US2
Posted date Jun 5, 2020
Country United States of America
Application number 201916453464
Gazette No. 20190314489
Date of filing Jun 26, 2019
Gazette Date Oct 17, 2019
Priority data
  • P2014-192753 (Sep 22, 2014) JP
  • 2015JP76681 (Sep 18, 2015) WO
  • 201715511988 (Mar 16, 2017) US
Title Cells for producing influenza virus and method for producing influenza virus
Abstract The present invention provides cells which have a high ability to propagate influenza virus, are suitable for use in production of an influenza virus for preparing a vaccine, and are able to be cultured in vitro, and a method for producing an influenza virus using the cells. That is, the present invention provides cells for producing an influenza virus in which expression of one or more genes that encode proteins involved in an effect of suppressing influenza virus production in a cell is suppressed and the gene is at least one selected from the group including ACTG1 gene and the like, and a method for producing an influenza virus that includes infecting the cells for producing an influenza virus with an influenza virus and then culturing.
Outline of related art and contending technology BACKGROUND ART
Influenza viruses cause epidemic diseases every year and sometimes cause pandemic diseases taking millions of victims. Influenza infection is generally prevented by preventive inoculation with a vaccine. The vaccine is obtained by inactivating influenza virus particles or partially decomposed products thereof. According to preventive inoculation with influenza vaccines, it is possible to reduce the risk of serious complications such as pneumonia, hospitalization and death when a person is infected with influenza.
Currently, vaccines are produced by inoculating embryonated chicken eggs with influenza viruses. Therefore, a large amount of embryonated chicken eggs need to be prepared for vaccine production. In addition, since production takes about six months, mass production of unexpected vaccines is difficult. In addition, allergic reactions due to egg components need to be considered.
Further, when influenza viruses are grown in chicken eggs, mutations are introduced into the viruses' genes, and antigenicity of the viruses changes in many cases. Actually, in recent years, in H3N2 type and B-type vaccines, antigenicity of a selected vaccine strain has matched that of an epidemic strain. However, mutations have been introduced into vaccine virus genes at the production stage, and antigenicity of produced vaccines has changed from the original vaccine strains. Therefore, there are situations in which “the vaccine effect is low even when an epidemic strain has been predicted correctly” (refer to Non Patent Literature 1).
Scope of claims [claim1]
1. Cells for producing an influenza virus which are HEK293 cells, Vero cells, or MDCK cells in which expression of at least one chromosomal gene is suppressed and which are able to be cultured in vitro,
wherein the at least one chromosomal gene is at least one gene selected from the group consisting of ACTG1 gene, ACTN1 gene, CCT6A gene, COPS7B gene, DAP3 gene, ERLIN2 gene, GNAI2 gene, GTF3C5 gene, HNRPAB gene, KHSRP gene, KRTI8 gene, MTCH1 gene, PPP2RIA gene, PRPS1 gene, RAB18 gene, RAB3A gene, RAPIB gene, RPS19 gene, RPS7 gene, S100A10 gene, SFRS7 gene, SLC2A12 gene, TMED2 gene, and USP10 gene.

[claim2]
2. The cells according to claim 1,
wherein the gene is deleted or disrupted.

[claim3]
3. The cells according to claim 1,
wherein the at least one chromosomal gene is at least one selected from the group including ACTG1 gene, ACTN1 gene, DAP3 gene, GNAI2 gene, GTF3C5 gene, KRT18 gene, MTCH1 gene, PRPS1 gene, RPS19 gene, S100A10 gene, SFRS7 gene, SLC2A12 gene, USP10 gene, PPP2RIA gene, and TMED2 gene.
4-6. (canceled)

[claim4]
7. The cells according to claim 1,
wherein the influenza virus is used to be formulated into an influenza virus vaccine.
8-9. (canceled)
  • Inventor, and Inventor/Applicant
  • KAWAOKA Yoshihiro
  • Watanabe Tokiko
  • Kawakami Eiryo
  • Watanabe Shinji
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
IPC(International Patent Classification)
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close